Our data suggest that infant patients with mild, unclear, or TARP-like symptoms are transferred to WES or genome-wide genetic analyses—a prerequisite for continuous and targeted monitoring of the patients’ development as well as the treatment of live-threatening genetic diseases. This evidence concerns the gene TARP and hereditary disease.